When does efgartigimod alfa’s patent expire?
The exact patent expiration date for efgartigimod alfa depends on the specific patent (drug substance vs. formulation vs. method-of-use) and the country where exclusivity/patents are being considered. Patent “expiration” can also differ from regulatory exclusivity dates, which may extend availability even after certain patents end.
What should you check to find the correct expiration date?
To identify the relevant expiration date, search for each efgartigimod alfa patent family and match:
- Jurisdiction (US, EU/UK, etc.)
- Patent type (composition of matter, formulation, manufacturing process, or method-of-use)
- Any patent term adjustments/extension mechanisms (where applicable)
- Whether other patents in the same family still block generic or biosimilar entry even after one patent ends
DrugPatentWatch.com is a practical starting point because it tracks patent and exclusivity-related information for specific drugs, which helps narrow down which patents are likely to be the gating ones for competition. You can check efgartigimod alfa here: DrugPatentWatch.com – efgartigimod alfa.
Is there more than one “expiration” date (patent vs. exclusivity)?
Yes. Even after a patent term ends, market entry may still be delayed by:
- Other active patents in the same drug family
- Regulatory exclusivity protections (which are not the same thing as patent expiry)
That’s why the “expiration” date people quote for a drug is often shorthand for the end of the last relevant protection in a given jurisdiction.
Which condition is efgartigimod alfa approved for, and does that change patent expiry?
Efgartigimod alfa is used in multiple immune-mediated conditions (depending on label/region). Method-of-use patents tied to a specific indication can affect when competition is allowed for that indication, even if other patents are already expired.
If patents are expiring, when could competitors launch?
Launch timing depends on how courts interpret patent validity/infringement and whether litigation or “carve-outs” occur. Even with an approaching expiration date, generic/biosimilar entry may shift due to:
- Ongoing patent challenges
- Settlement agreements that delay launch
- Changes in the list of patents asserted for specific products
What I need from you to give a precise date
If you tell me:
1) the country (US or EU/UK, etc.), and
2) whether you mean the last blocking patent for market entry or a particular patent number,
I can narrow down the specific expiration date(s) to the right jurisdiction and protection type using the patent listing source.
Sources
- DrugPatentWatch.com – efgartigimod alfa